Orlistat Weight Loss Pills: How They Work

Orlistat weight loss pills are one of the most widely used pharmaceutical treatments for obesity in the UK, available both on NHS prescription and over the counter from pharmacies. Orlistat works by blocking roughly a third of dietary fat from being absorbed, helping adults with a BMI of 28 or above manage their weight alongside a reduced-calorie diet. This article explains how orlistat works, who qualifies for NHS treatment, what realistic weight loss to expect, and which side effects to monitor, drawing on NICE guidance, MHRA authorisation, and current BNF recommendations.

What are orlistat weight loss pills and how do they work?

Orlistat inhibits gut lipase enzymes, blocking roughly one third of dietary fat from being absorbed so it is excreted rather than stored. It acts locally in the gastrointestinal tract and has no effect on the brain or appetite.

Orlistat weight loss pills work by blocking roughly one third of the fat you eat from being absorbed by your body.^[16][3] Orlistat belongs to a class of medicines called lipase inhibitors. Lipases are enzymes produced in the gut that break down dietary fat so it can pass through the intestinal wall into the bloodstream. By inhibiting these enzymes, orlistat prevents a significant portion of ingested fat from being digested, meaning it passes through the gut and is excreted in stools rather than stored as body fat.

In the UK, orlistat is available in two forms. The prescription-strength capsule contains 120 mg and is taken three times daily with meals; this version is licensed as Xenical. A lower-dose 60 mg capsule is available over the counter from pharmacies under the brand name Alli, for adults aged 18 and over with a body mass index (BMI) of 28 or above.^[4][9] Both formulations are MHRA-authorised medicines.

Orlistat capsules should be taken with each main meal that contains fat, or up to one hour after eating. If a meal is missed, or if a meal contains no fat, the dose should be skipped. This is standard advice from the UK patient information leaflets for both Xenical and Alli.

Alli 60 mg is intended for short-term use and is generally recommended for no longer than six months without medical review.^[9][4] If you have been using Alli for six months without achieving meaningful weight loss, you should speak to a pharmacist or GP about whether to continue.

Orlistat is not an appetite suppressant and does not act on the brain or central nervous system. Its effect is entirely local within the gastrointestinal tract. Because it only blocks fat absorption, the medicine works best when combined with a reduced-calorie, lower-fat diet. Eating a high-fat meal while taking orlistat significantly increases the likelihood of gastrointestinal side effects, which is an important practical consideration for anyone starting treatment. Orlistat does not affect the absorption of carbohydrates or protein, so overall dietary balance remains important throughout treatment.

Who can get orlistat on the NHS and are you eligible?

NICE recommends NHS orlistat for adults with a BMI of 30 or above, or 28 or above with a weight-related condition such as type 2 diabetes or hypertension. Continuation beyond 12 weeks requires at least 5% initial body weight loss.

Orlistat is available on the NHS for adults who meet specific clinical criteria set out in NICE guidance. NICE recommends prescribing orlistat 120 mg for adults with a BMI of 30 or above, or a BMI of 28 or above if they also have a weight-related condition such as type 2 diabetes, high blood pressure, or raised cholesterol.^[2][5] Eligibility is assessed by a GP or other qualified prescriber, who will also consider whether the person has already made meaningful dietary and lifestyle changes before starting medication.

NICE guidance also states that orlistat should only be continued beyond 12 weeks if the person has lost at least 5% of their initial body weight.^[2][5] For people with type 2 diabetes, weight loss may be slower and continuation targets may be set on an individualised basis; your prescriber will advise you. If the general threshold is not met, the prescriber will typically review whether continuing treatment is appropriate. In England, local commissioning decisions are made by Integrated Care Boards (ICBs), so availability and the precise criteria applied may vary across different parts of England. Scotland, Wales, and Northern Ireland have their own separate commissioning and prescribing arrangements, and eligibility criteria may differ accordingly.

Orlistat is not suitable for everyone. It should not be taken during pregnancy or breastfeeding. Women of childbearing potential should be aware that if severe diarrhoea occurs while taking orlistat, the absorption of oral contraceptives may be reduced, and additional contraceptive precautions should be used during and shortly after any episode of severe diarrhoea. This advice is set out in the UK SmPC for Xenical; discuss it with your prescriber or pharmacist if you have any concerns.

Orlistat is contraindicated in people with chronic malabsorption syndrome or cholestasis.^[1][6] Several important interactions should be discussed with a prescriber before starting treatment:

• Ciclosporin: Co-administration is generally not recommended. If unavoidable, ciclosporin blood levels should be monitored closely and doses separated.

• Warfarin and other anticoagulants: Orlistat may affect vitamin K absorption, which can alter the anticoagulant effect. INR should be monitored more frequently when starting or stopping orlistat.

• Levothyroxine: Orlistat may reduce levothyroxine absorption. Doses should be separated by at least four hours, and thyroid function (TSH) should be monitored.

• Amiodarone: Orlistat may reduce amiodarone exposure; inform your prescriber if you are taking this medicine.

• Antiepileptic medicines: Orlistat can affect the absorption of some antiepileptic drugs; your prescriber should be informed.

For those exploring weight management options more broadly, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of clinically appropriate treatments may be considered.

How much weight can you realistically lose taking orlistat?

Clinical trials show orlistat 120 mg typically produces around 3 to 5 kg more weight loss than placebo over one year when combined with a reduced-calorie diet. Results are modest and gradual, not rapid or dramatic.

Clinical evidence shows that orlistat, when combined with a reduced-calorie diet and increased physical activity, produces modest but meaningful weight loss compared with lifestyle changes alone. Evidence from clinical trials and systematic reviews, including Cochrane analyses, indicates that people taking orlistat 120 mg three times daily typically lose around 3 to 5 kg more than those on placebo over one year, which often corresponds to approximately 5% to 10% of initial body weight in those who respond to treatment.^[10][11] Weight loss of this magnitude is associated with clinically relevant improvements in blood pressure, blood glucose, and lipid levels.

It is important to set realistic expectations. Orlistat is not a rapid or dramatic weight loss treatment. The medicine works gradually, and the greatest benefit is seen in people who consistently follow a lower-fat diet alongside taking the capsules. Because orlistat only blocks fat absorption, eating a diet that remains high in fat will not only reduce the medicine's effectiveness but will also increase the risk of unpleasant gastrointestinal side effects.

NICE guidance uses the 5% weight loss at 12 weeks as a practical benchmark for continued prescribing. People with type 2 diabetes may have a less stringent or individualised target, and your prescriber will advise on this. People who achieve the general threshold are more likely to benefit from longer-term treatment. Prescription orlistat (Xenical 120 mg) is typically prescribed for up to 12 months; continuation beyond this period may be considered under specialist supervision where clinically justified, in line with BNF and NICE guidance. Alli 60 mg, available over the counter, is generally recommended for no longer than six months.

Weight regain after stopping orlistat is common if lifestyle changes are not maintained, which underlines the importance of treating orlistat as one component of a broader, sustained approach to weight management rather than a standalone solution.

What side effects should you watch out for with orlistat?

The most common side effects are gastrointestinal, including oily stools, urgent bowel movements, and flatulence, and are worse after high-fat meals. Serious but rare risks include liver injury, pancreatitis, and kidney problems requiring prompt medical attention.

The most common side effects of orlistat are gastrointestinal and are directly related to its mechanism of action, occurring when undigested fat passes through the bowel. These include:

• Oily or fatty stools

• Oily spotting on underwear

• Frequent or urgent bowel movements

• Flatulence, sometimes with an oily discharge

• Stomach pain or discomfort

These effects are more pronounced after high-fat meals and tend to improve as people adjust their diet to reduce fat intake. Keeping dietary fat to no more than around 30% of total calorie intake is generally recommended to minimise these symptoms. Spreading fat intake evenly across three meals rather than consuming it in one sitting can also help.

Orlistat can reduce the absorption of fat-soluble vitamins, specifically vitamins A, D, E, and K. People taking orlistat long-term are therefore advised to take a daily multivitamin supplement containing these vitamins, ideally at bedtime or at least two hours after the orlistat dose, to allow adequate absorption.

Serious side effects to be aware of include the following.

Liver problems: Cases of serious hepatic injury have been reported with orlistat.^[7][17] Seek prompt medical advice if you develop yellowing of the skin or whites of the eyes (jaundice), dark urine, itching, or pain in the upper right side of your abdomen. Stop taking orlistat and contact your GP or go to A&E if these symptoms are severe.

Pancreatitis: Acute pancreatitis has been reported in people taking orlistat, including cases of necrotising pancreatitis and cases with a fatal outcome.^[18][19] If you develop severe, persistent abdominal pain, contact your GP promptly. For symptoms that are sudden and severe, call 999 or go to A&E.

Kidney problems: Orlistat can increase the amount of oxalate absorbed from food, which may contribute to kidney stones or, rarely, oxalate nephropathy.^[1][3] People with chronic kidney disease should discuss this risk with their prescriber before starting orlistat. Seek medical review if you develop flank pain, blood in the urine, or difficulty passing urine.

Rectal bleeding: If you notice rectal bleeding while taking orlistat, consult your GP.

If you are unsure whether any symptom needs urgent attention, contact NHS 111 for advice.

Suspected side effects from orlistat can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps the MHRA monitor the safety of medicines in real-world use. Anyone taking orlistat who experiences unexpected or worsening symptoms should speak to their GP or pharmacist before stopping the medicine abruptly.

Scientific References

1. Xenical 120 mg hard capsules – Summary of Product Characteristics.
2. Overweight and obesity management – Prescribing orlistat, liraglutide and semaglutide (NG246).
3. Orlistat: a medicine to treat obesity.
4. Alli (previously Orlistat GSK) – European Public Assessment Report.
5. Orlistat – Drugs. BNF/NICE.
6. Xenical – Product Information (EPAR).
7. Orlistat safety update.
8. Xenical 120 mg – Patient Information Leaflet.
9. Alli 60 mg – Patient Information Leaflet.
10. One-year treatment of obesity: a randomized, double-blind, placebo-controlled study of orlistat. Finer N et al. Int J Obes Relat Metab Disord. 2000..
11. Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years with Orlistat. Davidson MH et al. JAMA. 1999..
12. Effects of orlistat on fat-soluble vitamins in obese adolescents. McDuffie JR et al. Pharmacotherapy. 2002..
13. Orlistat – Interactions. BNF/NICE.
14. Orlistat enhances warfarin effect. MacWalter RS et al. Ann Pharmacother. 2003..
15. Levothyroxine – Interactions. BNF/NICE.
16. Mode of action of orlistat. Guerciolini R. Int J Obes Relat Metab Disord. 1997..
17. European Medicines Agency starts review of orlistat-containing medicines.
18. Exploring Acute Pancreatitis After Orlistat Use: A Case Report. Cureus. 2025..
19. An Unexpected Result of Obesity Treatment: Orlistat-Related Acute Pancreatitis. Case Rep Gastroenterol. 2015..

Frequently Asked Questions